Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LUCD Stock Forecast 2026-2027
$1.30
Current Price
$219.77M
Market Cap
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to LUCD Price Targets
+592.3%
To High Target of $9.00
+130.8%
To Median Target of $3.00
+92.3%
To Low Target of $2.50
LUCD Price Momentum
-3.7%
1 Week Change
+4.0%
1 Month Change
+8.3%
1 Year Change
+19.3%
Year-to-Date Change
-23.5%
From 52W High of $1.70
+36.8%
From 52W Low of $0.95
📊 TOP ANALYST CALLS
Did LUCD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Lucid Diagnostics is one of their latest high-conviction picks.
Latest LUCD Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, LUCD has a bullish consensus with a median price target of $3.00 (ranging from $2.50 to $9.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $1.30, the median forecast implies a 130.8% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Edward Woo at Ascendiant Capital, projecting a 592.3% upside. Conversely, the most conservative target is provided by Mark Massaro at BTIG, suggesting a 92.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LUCD Analyst Ratings
5
Buy
0
Hold
0
Sell
LUCD Price Target Range
Low
$2.50
Average
$3.00
High
$9.00
Current: $1.30
Latest LUCD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LUCD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 9, 2026 | Ascendiant Capital | Edward Woo | Buy | Maintains | $9.00 |
| Mar 30, 2026 | BTIG | Mark Massaro | Buy | Reiterates | $2.50 |
| Mar 26, 2026 | Needham | Mike Matson | Buy | Reiterates | $3.00 |
| Dec 10, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $8.25 |
| Nov 13, 2025 | Needham | Mike Matson | Buy | Reiterates | $3.00 |
| Oct 6, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $8.00 |
| Sep 10, 2025 | BTIG | Mark Massaro | Buy | Reiterates | $2.50 |
| Sep 5, 2025 | BTIG | Mark Massaro | Buy | Maintains | $2.50 |
| Aug 13, 2025 | Needham | Mike Matson | Buy | Reiterates | $3.00 |
| Jul 16, 2025 | Needham | Mike Matson | Buy | Reiterates | $3.00 |
| Jun 6, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $7.75 |
| May 15, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $2.00 |
| May 14, 2025 | Needham | Mike Matson | Buy | Reiterates | $3.00 |
| Apr 21, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $7.50 |
| Apr 11, 2025 | Needham | Mike Matson | Buy | Reiterates | $3.00 |
| Mar 26, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $2.00 |
| Mar 24, 2025 | Needham | Mike Matson | Buy | Maintains | $3.00 |
| Dec 9, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $7.00 |
| Nov 15, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $2.00 |
| Nov 14, 2024 | Needham | Mike Matson | Buy | Reiterates | $2.50 |
Lucid Diagnostics Inc. (LUCD) Competitors
The following stocks are similar to Lucid Diagnostics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
LUCD
Lucid Diagnostics
mkt cap
212.95M
Lucid Diagnostics Inc. (LUCD) Financial Data
Lucid Diagnostics Inc. has a market capitalization of $219.77M with a P/E ratio of -3.0x. The company generates $4.71M in trailing twelve-month revenue with a -41.7% profit margin.
Revenue growth is +25.6% quarter-over-quarter, while maintaining an operating margin of -931.6% and return on equity of -710.6%.
Valuation Metrics
Market Cap
$219.77M
Enterprise Value
$265.87M
P/E Ratio
-3.0x
PEG Ratio
0.1x
Price/Sales
47.1x
Growth & Margins
Revenue Growth (YoY)
+25.6%
Gross Margin
-23.7%
Operating Margin
-931.6%
Net Margin
-41.7%
EPS Growth
+25.6%
Financial Health
Cash/Price Ratio
+16.2%
Current Ratio
1.3x
Debt/Equity
236.1x
ROE
-710.6%
ROA
-87.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Lucid Diagnostics Inc. (LUCD) Business Model
About Lucid Diagnostics Inc.
What They Do
Develops diagnostic tools for early cancer detection.
Business Model
The company generates revenue primarily through its innovative product, EsoCheck, which offers a less invasive and more efficient alternative to traditional diagnostic methods for esophageal conditions. By improving early diagnosis rates, Lucid Diagnostics not only enhances patient outcomes but also capitalizes on the growing demand for preventative healthcare solutions in the MedTech sector.
Additional Information
Lucid Diagnostics operates in a crucial niche within the healthcare industry, focusing on early detection technologies that improve patient care. Their commitment to increasing awareness and availability of non-invasive diagnostics positions them favorably as a key player in the evolving landscape of preventative healthcare.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
82
CEO
Dr. Lishan Aklog M.D.
Country
United States
IPO Year
2021
Website
www.luciddx.comLucid Diagnostics Inc. (LUCD) Latest News & Analysis
Latest News
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
12 days ago
Quick Summary
Lucid Diagnostics Inc. (Nasdaq: LUCD) CEO Lishan Aklog will speak at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026, at 10:15 AM EDT.
Why It Matters
Lucid Diagnostics' CEO's participation in a major healthcare conference could indicate strategic developments, attract investor interest, and impact stock performance in the medical diagnostics sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
PAVmed appoints a medtech veteran to lead its medical device portfolio. Its subsidiary, Octeris, Inc., will focus on developing endoscopic esophageal imaging technology licensed from Duke University.
Why It Matters
Leadership changes in PAVmed signal strategic focus on innovation, potentially enhancing growth and market position in medical devices, particularly with new technologies from Duke University.
Source: PRNewsWire
Market Sentiment:
Neutral
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
22 days ago
Quick Summary
PAVmed Inc. has strengthened its capital structure and relaunched its medical device portfolio. Lucid Diagnostics expanded access to EsoGuard, while Veris Health advanced partnerships and FDA submissions. A conference call will be held today at 8:30 AM EST.
Why It Matters
PAVmed's capital restructuring and product relaunch signal potential growth. Veris Health's partnership and Lucid Diagnostics' expansion could enhance market position, impacting share value and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Lucid Diagnostics Inc. (LUCD) held its Q4 2025 earnings call, discussing its financial performance and strategic initiatives. Further details on revenue and future outlook were provided.
Why It Matters
The earnings call provides insights into Lucid Diagnostics’ financial performance, growth prospects, and strategic direction, which can influence stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Lucid Diagnostics Inc. (LUCD) reported a quarterly loss of $0.10 per share, exceeding the Zacks Consensus Estimate of a $0.07 loss, and improved from a loss of $0.19 per share a year prior.
Why It Matters
Lucid Diagnostics' larger-than-expected loss signals potential struggles in meeting financial expectations, which may impact investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
26 days ago
Quick Summary
Lucid Diagnostics processed 3,664 EsoGuard tests, generating $1.5M in 4Q25 revenue. They secured a contract with the U.S. VA and reported positive data on esophageal precancer detection.
Why It Matters
Lucid Diagnostics' revenue growth and contract with the VA enhance credibility and market presence, signaling potential for increased investor confidence and stock value.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About LUCD Stock
What is Lucid Diagnostics Inc.'s (LUCD) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Lucid Diagnostics Inc. (LUCD) has a median price target of $3.00. The highest price target is $9.00 and the lowest is $2.50.
Is LUCD stock a good investment in 2026?
According to current analyst ratings, LUCD has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.30. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LUCD stock?
Wall Street analysts predict LUCD stock could reach $3.00 in the next 12 months. This represents a 130.8% increase from the current price of $1.30. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lucid Diagnostics Inc.'s business model?
The company generates revenue primarily through its innovative product, EsoCheck, which offers a less invasive and more efficient alternative to traditional diagnostic methods for esophageal conditions. By improving early diagnosis rates, Lucid Diagnostics not only enhances patient outcomes but also capitalizes on the growing demand for preventative healthcare solutions in the MedTech sector.
What is the highest forecasted price for LUCD Lucid Diagnostics Inc.?
The highest price target for LUCD is $9.00 from Edward Woo at Ascendiant Capital, which represents a 592.3% increase from the current price of $1.30.
What is the lowest forecasted price for LUCD Lucid Diagnostics Inc.?
The lowest price target for LUCD is $2.50 from Mark Massaro at BTIG, which represents a 92.3% increase from the current price of $1.30.
What is the overall LUCD consensus from analysts for Lucid Diagnostics Inc.?
The overall analyst consensus for LUCD is bullish. Out of 7 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are LUCD stock price projections?
Stock price projections, including those for Lucid Diagnostics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 21, 2026 9:19 PM UTC